Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Phase 4CompletedNCT00224146

Watson Pharmaceuticals2,878 enrolled

Overview

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,878

Conditions

Overactive Bladder Urinary Incontinence Quality of Life

Interventions

oxybutynin transdermal delivery system (Oxytrol(r))DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency Exclusion Criteria: * Patients for whom Oxytrol(r) is contraindicated. * Patients treated with Oxytrol(r) prior to participation in this study. * Patients residing in long-term care facilities or nursing homes.

Locations (10)

Unnamed facility

Mobile, Alabama, United States

Unnamed facility

Tucson, Arizona, United States

Unnamed facility

Torrance, California, United States

Unnamed facility

Rocky Hill, Connecticut, United States

Outcomes

Primary Outcomes

Change in health-related quality of life

Secondary Outcomes

Change in other outcomes such as:

depression

work productivity

participant satisfaction

effect of enhanced patient education on any of the above outcomes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.